Jill O’Donnell-Tormey, PhD, is the CEO and director of scientific affairs at the Cancer Research Institute.
In this episode, she discusses the history of cancer immunotherapy, recent breakthroughs, and the role that focused ultrasound may play in enhancing immunotherapy treatments.
Researchers used in vivo selection to engineer new adeno-associated virus vectors specifically designed for brain gene therapy delivered with focused ultrasound blood-brain barrier opening.
The newly created gene vectors provided more than a ten-fold improvement in delivering genes to specific regions of the brain.
Ellen Bubrick, MD, associate professor of Neurology at Harvard Medical School, was awarded a Citizens United for Research in Epilepsy (CURE) Epilepsy Catalyst Award.
She has pioneered a potential epilepsy treatment using low-intensity focused ultrasound and will use the $250,000 award to investigate optimal dosing for transcranial ultrasound.
“Cancer immunotherapy is a big word that encompasses a lot of things, but in its basic terms, it's using treatments that capitalize on the natural ability of your immune system to recognize threats and eliminate them.”
‒ Jill O’Donnell-Tormey, PhD, on the Curing with Sound podcast